Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) Return on Invested Capital (2017 - 2023)

Lineage Cell Therapeutics' Return on Invested Capital history spans 6 years, with the latest figure at 0.35% for Q4 2023.

  • For Q4 2023, Return on Invested Capital fell 22.0% year-over-year to 0.35%; the TTM value through Dec 2023 reached 0.35%, down 22.0%, while the annual FY2025 figure was 0.56%, N/A changed from the prior year.
  • Return on Invested Capital reached 0.35% in Q4 2023 per LCTX's latest filing, down from 0.34% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.02% in Q3 2021 to a low of 0.4% in Q3 2022.
  • Average Return on Invested Capital over 4 years is 0.28%, with a median of 0.32% recorded in 2023.
  • Peak YoY movement for Return on Invested Capital: tumbled -37bps in 2022, then grew 6bps in 2023.
  • A 4-year view of Return on Invested Capital shows it stood at 0.21% in 2019, then skyrocketed by 89bps to 0.02% in 2021, then crashed by -478bps to 0.13% in 2022, then tumbled by -169bps to 0.35% in 2023.
  • Per Business Quant, the three most recent readings for LCTX's Return on Invested Capital are 0.35% (Q4 2023), 0.34% (Q3 2023), and 0.32% (Q2 2023).